TSRI's CEO Peter Schultz and President Steve Kay share their reflections about the institute's accomplishments during the past year and their efforts toward shaping a bright future.
The study from the Duckett and Roush labs and colleagues points to an enzyme called casein kinase 1δ as a novel and highly vulnerable therapeutic target.
The study from the Wilson lab shows different branches of antibodies have developed different strategies to get around HIV's defenses.
The Davis lab will investigate a specific type of neuron whose overall function degrades with age.